Gilead Sciences 4th-qtr gets $1.9 billion boost from Veklury sales
US biotech Gilead Sciences (Nasdaq: GILD) late yesterday posted a strong set of 2020 fourth-quarter and full-year financial results, which saw its shares close up 2%, and a rise a further 2% to $67.15 pre-market today.
Fourth-quarter sales rose 26% to $7.3 billon, beating FactSet forecasts of $7.08 billion. What was not anticipated was the significant contribution from Gilead’s COVID-19 treatment Veklury (remdesivir), which generated revenues of $1.9 billion in the quarter, and $2.8 billion over the full year.
Net income fell 42% to $1.6 billion. Diluted earnings per share (EPS) were $1.23 and non-generally accepted accounting principles (GAAP) EPS was $2.19, up 99%, beating the average estimate of analysts polled by FactSet for $2.04.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze